Privacy·Terms·Disclaimer

Bibliographic data courtesy of the U.S. National Library of Medicine (NLM), sourced from PubMed/MEDLINE.

SciRadar is not affiliated with, endorsed by, or sponsored by NLM or NCBI. Abstracts remain © their respective publishers.

Inluriyo (imlunestrant) for ESR1-mutant breast cancer: modest gains, unmet concerns. — SciRadar

Back to results

Annals of medicine and surgery (2012)

Inluriyo (imlunestrant) for ESR1-mutant breast cancer: modest gains, unmet concerns.

Zehra Sadia, Zarmeen Azhar, Joshua Ekouo

Published: 202610.1097/MS9.0000000000004357

No abstract available for this study.